GW Pharmaceuticals Announces New Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy
- Category: Medical Cannabis News
- Published: Friday, 17 October 2014 11:44
14 October 2014: GW Pharmaceuticals plc announced new physician reports of efficacy and safety associated with the Epidiolex® “expanded access” studies.
Physician reports of efficacy and safety data have been made available on 58 children and young adults with treatment-resistant epilepsy who have been treated with GW’s investigational cannabidiol (CBD) product candidate, Epidiolex, for a period of at least 12 weeks. This includes 27 patients on whom data was reported in June 2014 and an additional 31 patients on whom data has recently been made available to the Company. In addition, of the 58 total patients, 40 patients have been treated for at least 16 weeks and data has been available for this time period also. These data are from three hospital sites in the United States and were generated under expanded access Investigational New Drug applications (INDs) authorized by the U.S. Food and Drug Administration (FDA). In addition, physician reports of safety data were made available on 151 patients (58 patients with 12 weeks treatment effect data plus 93 additional patients for whom 12 week treatment effect data is not yet available).